- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01083810
Evaluation of Kaletra Therapy Over the Long-term
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Three to five year observation of lopinavir/ritonavir therapy. Reporting groups are 1) therapy-naïve patients (144 weeks), 2) therapy-experienced but protease inhibitor naïve patients (240 weeks,) and 3) non-B subtype infected patients (240 weeks).
These three groups of participants with HIV-1 infection were at first registered as three different studies: KAL1RO (this study, NCT01083810, n=137), KAL2RO /KAL5RO (NCT01083836, n=92), and KAL6RO (NCT01081470, n=55) but were now reconciled under KAL1RO (NCT01083810) as a single study with three reporting groups.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Aachen, Alemanha, 52062
- Site Ref # / Investigator 27706
-
Aachen, Alemanha, 52062
- Site Ref # / Investigator 52972
-
Berlin, Alemanha, 10117
- Site Ref # / Investigator 27660
-
Berlin, Alemanha, 10117
- Site Ref # / Investigator 27937
-
Berlin, Alemanha, 10117
- Site Ref # / Investigator 52973
-
Berlin, Alemanha, 10243
- Site Reference ID/Investigator# 27629
-
Berlin, Alemanha, 10439
- Site Ref # / Investigator 27651
-
Berlin, Alemanha, 10439
- Site Ref # / Investigator 27912
-
Berlin, Alemanha, 10439
- Site Reference ID/Investigator# 27544
-
Berlin, Alemanha, 10551
- Site Reference ID/Investigator# 27567
-
Berlin, Alemanha, 10589
- Site Ref # / Investigator 27929
-
Berlin, Alemanha, 10707
- Site Ref # / Investigator 52971
-
Berlin, Alemanha, 10707
- Site Ref # / Investigator 53468
-
Berlin, Alemanha, 10777
- Site Ref # / Investigator 27965
-
Berlin, Alemanha, 10777
- Site Reference ID/Investigator# 27547
-
Berlin, Alemanha, 10777
- Site Reference ID/Investigator# 27552
-
Berlin, Alemanha, 10777
- Site Reference ID/Investigator# 27562
-
Berlin, Alemanha, 10961
- Site Ref # / Investigator 52984
-
Berlin, Alemanha, 13347
- Site Ref # / Investigator 27639
-
Berlin, Alemanha, 13347
- Site Ref # / Investigator 52970
-
Berlin, Alemanha, D-10243
- Site Ref # / Investigator 27909
-
Berlin, Alemanha, D-10243
- Site Ref # / Investigator 47113
-
Chemnitz, Alemanha, 09113
- Site Reference ID/Investigator# 27574
-
Cologne, Alemanha, 50674
- Site Ref # / Investigator 28060
-
Cologne, Alemanha, 50674
- Site Ref # / Investigator 52978
-
Cologne, Alemanha, 50679
- Site Ref # / Investigator 27932
-
Cologne, Alemanha, 50679
- Site Ref # / Investigator 52979
-
Cologne, Alemanha, 50931
- Site Ref # / Investigator 48233
-
Cologne, Alemanha, 50931
- Site Ref # / Investigator 52985
-
Cologne, Alemanha, 50931
- Site Ref # / Investigator 53464
-
Dortmund, Alemanha, 44137
- Site Ref # / Investigator 27704
-
Dortmund, Alemanha, 44137
- Site Ref # / Investigator 27947
-
Dortmund, Alemanha, 44137
- Site Ref # / Investigator 52968
-
Duesseldorf, Alemanha, 40237
- Site Ref # / Investigator 28056
-
Duisburg, Alemanha, 47259
- Site Reference ID/Investigator# 27558
-
Frankfurt, Alemanha, 15232
- Site Ref # / Investigator 52983
-
Frankfurt, Alemanha, 60311
- Site Ref # / Investigator 27928
-
Frankfurt, Alemanha, 60311
- Site Ref # / Investigator 52967
-
Freiburg, Alemanha, 79106
- Site Reference ID/Investigator# 27565
-
Fuerth, Alemanha, 90762
- Site Reference ID/Investigator# 27566
-
Fuerth, Alemanha, D-90762
- Site Ref # / Investigator 53465
-
Hamburg, Alemanha, 20099
- Site Ref # / Investigator 27931
-
Hamburg, Alemanha, 20099
- Site Ref # / Investigator 27982
-
Hamburg, Alemanha, 20099
- Site Ref # / Investigator 47114
-
Hamburg, Alemanha, 20099
- Site Ref # / Investigator 47115
-
Hamburg, Alemanha, 20099
- Site Reference ID/Investigator# 27551
-
Hamburg, Alemanha, 20099
- Site Reference ID/Investigator# 27634
-
Hamburg, Alemanha, 20146
- Site Ref # / Investigator 30864
-
Hamburg, Alemanha, 20146
- Site Ref # / Investigator 5348
-
Hamburg, Alemanha, 20146
- Site Reference ID/Investigator# 27546
-
Hamburg, Alemanha, 20246
- Site Ref # / Investigator 28032
-
Hamburg, Alemanha, 20246
- Site Ref # / Investigator 52969
-
Hamburg, Alemanha, 20246
- Site Ref # / Investigator 53467
-
Hamburg, Alemanha, 20354
- Site Ref # / Investigator 52980
-
Karlsruhe, Alemanha, 76135
- Site Ref # / Investigator 27641
-
Karlsruhe, Alemanha, 76135
- Site Ref # / Investigator 27964
-
Karlsruhe, Alemanha, 76135
- Site Reference ID/Investigator# 27561
-
Koblenz, Alemanha, 56065
- Site Ref # / Investigator 53466
-
Koblenz, Alemanha, 56065
- Site Reference ID/Investigator# 27555
-
Krefeld, Alemanha, 47800
- Site Ref # / Investigator 27905
-
Leipzig, Alemanha, 04107
- Site Ref # / Investigator 27906
-
Leipzig, Alemanha, 04107
- Site Ref # / Investigator 52975
-
Leipzig, Alemanha, 04107
- Site Ref # / Investigator 53463
-
Ludwigshafen, Alemanha, 67063
- Site Ref # / Investigator 27948
-
Ludwigshafen, Alemanha, 67063
- Site Ref # / Investigator 52977
-
Mainz, Alemanha, 55116
- Site Ref # / Investigator 27902
-
Mainz, Alemanha, 55116
- Site Reference ID/Investigator# 27543
-
Moenchengladbach, Alemanha, 41061
- Site Ref # / Investigator 28104
-
Moenchengladbach, Alemanha, 41061
- Site Ref # / Investigator 52981
-
Muenster, Alemanha, 48149
- Site Ref # / Investigator 27648
-
Muenster, Alemanha, 48149
- Site Reference ID/Investigator# 27568
-
Munich, Alemanha, 80337
- Site Ref # / Investigator 27949
-
Munich, Alemanha, 80337
- Site Reference ID/Investigator# 27553
-
Munich, Alemanha, 80801
- Site Ref # / Investigator 27926
-
Munich, Alemanha, 80801
- Site Ref # / Investigator 53462
-
Nuernberg, Alemanha, 90419
- Site Ref # / Investigator 52982
-
Oldenburg, Alemanha, 26121
- Site Ref # / Investigator 27988
-
Oldenburg, Alemanha, 26121
- Site Reference ID/Investigator# 27563
-
Osnabrueck, Alemanha, 49076
- Site Ref # / Investigator 27637
-
Osnabrueck, Alemanha, 49076
- Site Ref # / Investigator 27943
-
Osnabrueck, Alemanha, 49076
- Site Ref # / Investigator 52974
-
Paderborn, Alemanha, 33100
- Site Ref # / Investigator 27939
-
Rostock, Alemanha, 18057
- Site Ref # / Investigator 27649
-
Rostock, Alemanha, D-18057
- Site Reference ID/Investigator# 27569
-
Stuttgart, Alemanha, 70197
- Site Ref # / Investigator 27647
-
Stuttgart, Alemanha, 70197
- Site Ref # / Investigator 28047
-
Stuttgart, Alemanha, 70197
- Site Ref # / Investigator 28048
-
Stuttgart, Alemanha, 70197
- Site Reference ID/Investigator# 27631
-
Troisdorf, Alemanha, 53840
- Site Ref # / Investigator 52976
-
Wuppertal, Alemanha, 42277
- Site Ref # / Investigator 27961
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Patients infected by HIV-1
- Age greater than or equal to 18 years
Exclusion Criteria:
- as described in SmPC (summary of product characteristics) at the time of prescription
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
---|---|
therapy-naive
Patients who had not received prior antiretroviral drug therapy
|
3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
Outros nomes:
|
pre-treated
Patients that had previously received antiretroviral therapy, but are protease inhibitor naive
|
3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
Outros nomes:
|
non-B
Patients infected with non-B subtypes of HIV-1
|
3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Number of Patients With Virus That Develop Mutations Conferring Resistance to Lopinavir/Ritonavir, NRTIs or NNRTIs
Prazo: Baseline and at any timepoint where testing is possible
|
Standard genotypic resistance assays were developed for HIV-1 viral load levels greater than 500 to 1000 copies per milliliter (mL).
All 3 protocols recommended this testing be done at Baseline prior to lopinavir/ritonavir therapy and (if possible) in cases of virologic failure.
The exact timing varied and depended on whether there was an adequate viral load and physician clinical judgment.
Participants with resistance to lopinavir/ritonavir, nucleoside reverse transcriptase inhibitors (NRTI) or non-nucleoside reverse transcriptase inhibitors (NNRTI) at Baseline and follow-up are reported.
|
Baseline and at any timepoint where testing is possible
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Percentage of Patients With HIV-1 RNA <50 Copies/ml
Prazo: Baseline, Week 4, 12, 24, followed by 12-week intervals up to 144/240 weeks
|
All 3 protocols recommended that HIV viral load tests be performed at Baseline and each study visit.
Study visits were to occur at approximately Weeks 4, 12, and 24, followed by 12-week intervals up to Week 144 in therapy-naive participants and up to Week 240 in the pre-treated and non-B subtype groups.
The percentage of participants with HIV-1 ribonucleic acid (RNA) less than 50 copies/mL at each time point is presented by subgroup.
|
Baseline, Week 4, 12, 24, followed by 12-week intervals up to 144/240 weeks
|
Percentage of Patients With HIV-1 RNA 50 to <200 Copies/ml
Prazo: Baseline, Week 4, 12, 24, followed by 12-week intervals up to 144/240 weeks
|
All 3 protocols recommended that HIV viral load tests be performed at Baseline and each study visit.
Study visits were to occur at approximately Weeks 4, 12, and 24, followed by 12-week intervals up to Week 144 in therapy-naive participants and up to Week 240 in the pre-treated and non-B subtype groups.
The percentage of participants with HIV-1 RNA levels of 50 to less than 200 copies/mL at each time point is presented by subgroup.
|
Baseline, Week 4, 12, 24, followed by 12-week intervals up to 144/240 weeks
|
Percentage of Patients With HIV-1 RNA 200 to <500 Copies/ml
Prazo: Baseline, Week 4, 12, 24, followed by 12-week intervals up to 144/240 weeks
|
All 3 protocols recommended that HIV viral load tests be performed at Baseline and each study visit.
Study visits were to occur at approximately Weeks 4, 12, and 24, followed by 12-week intervals up to Week 144 in therapy-naive participants and up to Week 240 in the pre-treated and non-B subtype groups.
The percentage of participants with HIV-1 RNA levels of 200 to less than 500 copies/mL at each time point is presented by subgroup.
|
Baseline, Week 4, 12, 24, followed by 12-week intervals up to 144/240 weeks
|
Percentage of Patients With HIV-1 RNA >500 Copies/ml
Prazo: Baseline, Week 4, 12, 24, followed by 12-week intervals up to 144/240 weeks
|
All 3 protocols recommended that HIV viral load tests be performed at Baseline and each study visit.
Study visits were to occur at approximately Weeks 4, 12, and 24, followed by 12-week intervals up to Week 144 in therapy-naive participants and up to Week 240 in the pre-treated and non-B subtype groups.
The percentage of participants with more than 500 HIV-1 RNA copies/mL at each time point is presented by subgroup.
|
Baseline, Week 4, 12, 24, followed by 12-week intervals up to 144/240 weeks
|
Change in Absolute CD4 Cell Count [CD4+ Cells/µL]
Prazo: Baseline, Week 4, 12, 24, followed by 12-week intervals up to 144/240 weeks
|
The evolution of participants' CD4-positive (CD4+) T-lymphocyte counts after starting the lopinavir/ritonavir-containing regimen was to be assessed by measuring the number of CD4+ cells at baseline and each subsequent study visit.
Study visits were to occur at approximately Weeks 4, 12, 24, followed by 12-week intervals up to Week 144 in therapy-naive participants and up to Week 240 in the pre-treated and non-B subtype groups.
CD4+ cell count results are reported as the change from Baseline in the absolute number of CD4+ cells per microliter.
|
Baseline, Week 4, 12, 24, followed by 12-week intervals up to 144/240 weeks
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções transmitidas pelo sangue
- Doenças Transmissíveis
- Doenças Sexualmente Transmissíveis, Virais
- Doenças Sexualmente Transmissíveis
- Infecções por Lentivírus
- Infecções por Retroviridae
- Doenças do sistema imunológico
- Doenças de Vírus Lento
- Infecções por HIV
- Síndrome da Imunodeficiência Adquirida
- Síndromes de Deficiência Imunológica
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Antivirais
- Inibidores Enzimáticos
- Agentes anti-HIV
- Antirretrovirais
- Inibidores de Protease
- Inibidores do citocromo P-450 CYP3A
- Inibidores da enzima citocromo P-450
- Inibidores da Protease do HIV
- Inibidores de Protease Viral
- Ritonavir
- Lopinavir
Outros números de identificação do estudo
- KAL 1 RO
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Vírus da imunodeficiência humana
-
Jinling Hospital, ChinaDesconhecidoDoença de Crohn | Metilação | Illumina Human Metilation 850k BeadChipChina
Ensaios clínicos em Lopinavir/Ritonavir (Kaletra)
-
Drugs for Neglected DiseasesUniversity of Cape Town; Medecins Sans Frontieres, Netherlands; UBS Optimus Foundation e outros colaboradoresConcluídoSíndrome da Imunodeficiência Adquirida | TuberculoseÁfrica do Sul
-
Oswaldo Cruz FoundationMinistry of Health, BrazilConcluídoInfecções por HIV | GravidezBrasil
-
AbbottConcluído
-
University College, LondonLifeArcConcluído
-
University of California, San DiegoAbbottConcluídoInfecção pelo HIVEstados Unidos
-
Fundacion SEIMC-GESIDAAbbottConcluídoInfecções por HIV | Infecção pelo HIV | LipodistrofiaEspanha
-
Fundacion SEIMC-GESIDAAbbottConcluídoInfecções por HIV | Coinfecção HIV/HCVEspanha
-
Institut National de la Santé Et de la Recherche...FUJIFILM Toyama Chemical Co., Ltd.RecrutamentoDoença infecciosa | FarmacologiaFrança
-
Germans Trias i Pujol HospitalFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción...Concluído